Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2022 > Johnson & Johnson Vision Care Receives FDA Approval for ACUVUE® Theravision™ with Ketotifen – World’s First and Only Drug-Eluting Contact Lens

Johnson & Johnson Vision Care Receives FDA Approval for ACUVUE® Theravision™ with Ketotifen – World’s First and Only Drug-Eluting Contact Lens

Johnson & Johnson Vision Care Receives FDA Approval for ACUVUE® Theravision™ with Ketotifen – World’s First and Only Drug-Eluting Contact Lens

Read also

UK approves GSK's twice-yearly asthma drug

UK approves GSK's twice-yearly asthma drug

Reuters - UK's health regulator on Monday approved GSK's (GSK.L), opens new tab twice-yearly drug for use as an add-on treatment for asthma in patients aged 12 and older, as well as fo...

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1

Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours

Sumitomo Pharma Presents Encouraging New Data on DSP-5336

Sumitomo Pharma Presents Encouraging New Data on DSP-5336

Sumitomo Pharma Presents Encouraging New Data on DSP-5336 Clinical Activity at the American Society of Hematology Annual Meeting

Lupin gets EIR from US FDA for Nagpur-based injectable facility

Lupin gets EIR from US FDA for Nagpur-based injectable facility

Lupin said that it has received the establishment inspection report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable facility in Nagpur, India, wit...